Message from Director
PBPL’s mission is to contribute to the enrichment of the quality of life around the world through the creation of innovative lab grade products and through the provision of pharmaceuticals that address diverse medical needs.
The business environment facing the pharmaceutical industry continues to evolve in India and around the world. In the midst of these changing conditions, we are working to realize our 2025 vision of being a Global Pharma & laboratory grade products Innovator with Competitive Advantage in healthcare. To that end, we are striving to satisfy unmet medical needs by providing of laboratory products, surgical products, new drugs, including vaccines, generic and OTC drugs, to hospitals that meet a variety of medical needs.
As a leader in the healthcare industry, we recognize that we have multiple responsibilities to our many stakeholders. We not only have a responsibility to provide the pharmaceuticals that are indispensable today to healthcare systems around the world, but we must also fund the research and development that ensures the availability of tomorrow’s innovative medicines. We also have a responsibility to support the communities in which we live and work. We commit to achieving these important goals while delivering earnings growth to our shareholders and doing our utmost to earn the trust of all our stakeholders. By embracing these responsibilities, we hope to be a company worthy of representing India as a cutting-edge global enterprise.
We will continue advancing R&D to “create value” that society truly needs and contribute to realizing a prosperous society while supporting the sustainability of our operations, both economically and environmentally.
Thank you for your continued support.
Managing Director,
Prem Shankar Jha
Message from R&D department
We are in a new era of lab-grade chemicals, surgical products & medicine where breakthrough science is transforming care and our approach in healthcare.
Creating new research themes is a top priority for R&D. I think that there are three approaches to achieving it. The first approach is to backcast from future predictions for a few decades ahead and decides a large-scale project theme in a top-down fashion while ensuring the consistency of our company’s technology with the market. The second approach is a bottom-up type that does not consolidate themes into limited ones, but supports researchers’ initiatives and sets a number of themes quickly while having a dialogue with the market. The third approach is to create themes by delving into science with a technology platform at the core. Each of these approaches has their own advantages, so our company will not depend on just one of them. Instead, we will flexibly respond to the movement of the times by frequently using open innovation while we will delve into science with well balancing top-down and bottom-up approaches.
R&D Division is seeking to create new formulas that provide value to healthcare in the form of quality and price. With our market becoming both more diverse and more complex, we are currently developing new products with new technologies focused on specific issues where qualities of our products have the potential to provide solutions.
We will continue seeking to create new value by improving our existing technologies, innovating new technologies, and producing a steady stream of new products and new businesses. We are maximizing our R&D capabilities by improving intercommunication across the Group to realize the full potential of our products. We will also seek out partnerships with companies, groups, and research institutions that can serve as catalysts to achieving our goals.
Department Head (R&D),
Sumera Naz